EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudie

Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study

Alessandro Costa iD, Emilia Scalzulli, Ida Carmosino, Maria Laura Bisegna, Alessandro Laganà, Claudia Ielo, Luca Cappelli iD, Maurizio Martelli, Massimo Breccia iD

British Journal of Haematology · 2026-05 · 208 (5) · 1669-1678

DOI: 10.1111/bjh.70418 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 12.03.2026. Verfasst von Alessandro Costa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myeloid, Chronic-Phase, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imatinib has revolutionized the management of chronic‐phase chronic myeloid leukaemia (CP‐CML). This study aimed to evaluate the long‐term efficacy, safety and prognostic determinants of imatinib in a large cohort of CP‐CML patients in real‐life clinical practice. We conducted a retrospective, monocentric observational study including all adult patients with CP‐CML treated with imatinib between 2000 and 2025. Overall survival (OS), event‐free survival (EFS) and progression‐free survival (PFS) were estimated using Kaplan–Meier analysis. A total of 210 patients were included, of whom 81% received imatinib as first‐line therapy. The median follow‐up was 12.4 years. At 25 years, OS and PFS were 71% and 88% respectively. The EUTOS long‐term survival (ELTS) score independently predicted OS, EFS and PFS ( p < 0.001), while lower risk categories were associated with a faster achievement of major molecular response (MMR) and a higher probability of deep molecular response (DMR). Dose reductions were applied in 26.2% of patients, mainly older individuals with higher Charlson comorbidity index (CCI), without affecting molecular or survival outcomes. Higher CCI values correlated with inferior OS. The ELTS score remains a powerful prognostic tool for long‐term outcomes. No unexpected safety concerns were observed in the long term. Over 25 years of real‐world experience, imatinib has demonstrated sustained efficacy, safety and tolerability in CP‐CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateLeukemia, Myeloid, Chronic-PhaseAntineoplastic AgentsProtein Kinase InhibitorsHumansFemaleMiddle AgedAdultMaleRetrospective StudiesAgedTreatment OutcomeFollow-Up StudiesAged, 80 and over

Stichwörter der Autor:innen

efficacyimatiniblong‐term follow‐upoutcomessafety

Substanzen

Imatinib MesylateAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.

ORCID-Profile: Alessandro Costa, Luca Cappelli, Massimo Breccia

Zitieren

APA

Costa, A., Scalzulli, E., Carmosino, I., Bisegna, M. L., Laganà, A., Ielo, C., Cappelli, L., Martelli, M., & Breccia, M. (2026). Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study. British Journal of Haematology, 208(5), 1669-1678. https://doi.org/10.1111/bjh.70418

Vancouver

Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, et al. Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study. British Journal of Haematology. 2026;208(5):1669-1678. doi:10.1111/bjh.70418

BibTeX
@article{Costa2026,
  author = {Costa, Alessandro and Scalzulli, Emilia and Carmosino, Ida and Bisegna, Maria Laura and Laganà, Alessandro and Ielo, Claudia and Cappelli, Luca and Martelli, Maurizio and Breccia, Massimo},
  title = {Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {5},
  pages = {1669--1678},
  doi = {10.1111/bjh.70418}
}
Kostenlos starten →